Related Experiment Video

Updated: Apr 6, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Minimizing Hypoglycemia in Diabetes

    Diabetes Care
    |July 25, 2015
    PubMed

    Insights

    Hypoglycemia from diabetes medications like sulfonylureas, glinides, or insulin can be recurrent and dangerous. Managing diabetes risk factors and employing intensive glycemic therapy can significantly reduce hypoglycemia incidence and severity.

    Area of Science:

    • Endocrinology
    • Metabolic Diseases
    • Pharmacology

    Background:

    • Hypoglycemia is a significant complication for individuals with diabetes treated with sulfonylureas, glinides, or insulin.
    • Recurrent hypoglycemia leads to morbidity, mortality, impaired glycemic control, and diminished physiological and behavioral defenses.

    Purpose of the Study:

    • To outline strategies for minimizing iatrogenic hypoglycemia in people with diabetes.
    • To emphasize the importance of individualized glycemic goals and patient education.

    Main Methods:

    • Review of risk factors associated with hypoglycemia.
    • Application of intensive glycemic therapy principles, including drug selection and technology use.
    • Structured patient education and individualized glycemic goal setting.

    Main Results:

    • Minimizing hypoglycemia requires acknowledging risks, considering factors, and applying therapeutic principles.
    • Individualized glycemic goals and structured education reduce hypoglycemia incidence.
    • Short-term avoidance of hypoglycemia can reverse impaired awareness.

    Conclusions:

    • The risk of iatrogenic hypoglycemia in diabetes management is modifiable.
    • A comprehensive approach involving risk assessment, appropriate therapy, and patient education is crucial.
    • Effective management strategies can improve patient safety and glycemic control.

    More Related Videos

    Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique07:35

    Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

    Published on: January 26, 2024

    2.4K
    Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

    Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

    Published on: November 16, 2011

    96.2K

    Related Concept Videos

    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    1.3K
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
    961
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are...
    888
    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
    965
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    1.2K
    Diabetes: Management and Pharmacotherapy01:15

    Diabetes: Management and Pharmacotherapy

    The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
    Insulin remains the cornerstone of treatment for most patients with type 1 and many...
    1.5K